<DOC>
	<DOCNO>NCT01437982</DOCNO>
	<brief_summary>The objective study identify adverse event adverse drug reaction post-marketing surveillance routine clinical practice</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Lotemax Ophthalmic Suspension 0.5 %</brief_title>
	<detailed_description>The objective study identify adverse event adverse drug reaction post-marketing surveillance routine clinical practice marketing authorization Lotemax ophthalmic suspension 0.5 %</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Subjects treat study drug least complete safety followup . Subjects treat study drug least complete clinical efficacy assessment . Subjects treat study drug least .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>post-operative inflammation</keyword>
	<keyword>conjunctivitis</keyword>
	<keyword>safety</keyword>
	<keyword>Seasonal allergic conjunctivitis</keyword>
	<keyword>Giant papillary conjunctivitis</keyword>
</DOC>